WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

C CARDIOVASCULAR SYSTEM
C10 LIPID MODIFYING AGENTS

The DDDs are based on the treatment of hypercholesterolemia.


C10B LIPID MODIFYING AGENTS, COMBINATIONS

Fixed combinations of blood glucose-lowering drugs and lipid modifying agents are classified in A10B.

For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.


C10BA HMG CoA reductase inhibitors in combination with other lipid modifying agents
C10BX HMG CoA reductase inhibitors, other combinations

Combinations with e.g. ACE inhibitors, angiotensin II antagonists, calcium channel blockers or diuretics are classified in C10BX.

Last updated: 2018-12-13